Sapience Investments LLC increased its holdings in shares of Davita Inc (NYSE:DVA) by 16.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,700 shares of the company’s stock after acquiring an additional 8,570 shares during the quarter. Sapience Investments LLC’s holdings in Davita were worth $3,471,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of DVA. Pictet Asset Management Ltd. lifted its holdings in Davita by 3,290.3% during the second quarter. Pictet Asset Management Ltd. now owns 1,132,521 shares of the company’s stock worth $63,716,000 after acquiring an additional 1,168,020 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in Davita by 1,512.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 724,095 shares of the company’s stock worth $40,159,000 after acquiring an additional 679,199 shares during the period. DPM Capital LLC lifted its holdings in Davita by 90.3% during the first quarter. DPM Capital LLC now owns 1,339,099 shares of the company’s stock worth $72,700,000 after acquiring an additional 635,250 shares during the period. Tavio Capital LLC bought a new stake in Davita during the second quarter worth $11,609,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in Davita by 30.5% during the first quarter. Parametric Portfolio Associates LLC now owns 503,062 shares of the company’s stock worth $27,311,000 after acquiring an additional 117,554 shares during the period. Institutional investors and hedge funds own 90.71% of the company’s stock.
DVA has been the topic of a number of recent analyst reports. SunTrust Banks reiterated a “hold” rating and set a $68.00 price target on shares of Davita in a report on Wednesday, September 11th. UBS Group lowered their target price on Davita from $61.00 to $60.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. TheStreet upgraded Davita from a “c+” rating to a “b-” rating in a research note on Wednesday, July 24th. Robert W. Baird lowered Davita from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $70.00 to $65.00 in a research note on Friday, July 26th. Finally, William Blair lowered Davita from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $67.31.
Shares of DVA traded up $1.29 during mid-day trading on Monday, hitting $63.15. The stock had a trading volume of 198,068 shares, compared to its average volume of 3,463,318. The firm has a market cap of $9.95 billion, a P/E ratio of 17.78, a PEG ratio of 0.60 and a beta of 1.59. The business has a fifty day moving average price of $58.29 and a 200-day moving average price of $54.38. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.12 and a quick ratio of 1.10. Davita Inc has a 52 week low of $43.40 and a 52 week high of $79.11.
Davita (NYSE:DVA) last issued its earnings results on Thursday, August 1st. The company reported $1.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.12. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.86 billion. Davita had a return on equity of 14.67% and a net margin of 1.21%. The business’s revenue was down 1.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.05 earnings per share. As a group, research analysts expect that Davita Inc will post 4.78 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading: Fundamental Analysis and Individual Investors
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.